This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for COWZ
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.
CVS Health (CVS) Gains From Digital Adoption Amid Competition
by Zacks Equity Research
CVS Health (CVS) has been removing barriers to digital adoption and making it easier for customers to access services such as pharmacy refills and advanced scheduling for immunizations online.
The Zacks Analyst Blog Highlights NIKE, Airbnb, CVS Health, ONEOK and Arch Capital
by Zacks Equity Research
NIKE, Airbnb, CVS Health, ONEOK and Arch Capital are included in this Analyst Blog.
Q4 Earnings Scorecard and Fresh Analyst Reports for Nike, Airbnb & CVS Health
by Sheraz Mian
Today's Research Daily features a real-time earnings season update and new research reports on NIKE (NKE), Airbnb (ABNB), CVS Health (CVS) and others.
Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
by Zacks Equity Research
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CVS Health (CVS) Q4 Earnings Top Estimates, 2024 EPS View Down
by Zacks Equity Research
Robust sales growth across all three operating segments contributes to CVS Health's (CVS) Q4 revenues.
Compared to Estimates, CVS Health (CVS) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for CVS Health (CVS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Why Investors Need to Take Advantage of These 2 Retail and Wholesale Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Exploring Analyst Estimates for CVS Health (CVS) Q4 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of CVS Health (CVS) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
CVS Health (CVS) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, CVS Health (CVS) closed at $73.92, marking a -0.61% move from the previous day.
CVS Health (CVS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
CVS Health (CVS) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, CVS Health (CVS) stood at $73, denoting a +1.4% change from the preceding trading day.
CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) fourth-quarter 2023 results are likely to reflect the strength of the Pharmacy & Consumer Wellness and Health Services segments.
CVS Health (CVS) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, CVS Health (CVS) closed at $73.22, indicating a -0.89% shift from the previous trading day.
Is Trending Stock CVS Health Corporation (CVS) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
What's in the Cards for Fastenal (FAST) in Q4 Earnings?
by Zacks Equity Research
Fastenal's (FAST) Q4 results are likely to reflect manufacturing growth, albeit at a slow pace, with a strong digital strategy and a balanced onsite/offsite mix. Yet, slowing industrial markets are a concern.
How to Boost Your Portfolio with Top Retail and Wholesale Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Company News for Jan 12, 2024
by Nalak Das
Companies In the News Are: INFY, GOOGL, CVS, TGT, C.
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CVS Health (CVS) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
The latest trading day saw CVS Health (CVS) settling at $79.24, representing a -1.39% change from its previous close.
Zacks Industry Outlook Highlights CVS Health, Herbalife, Rite Aid and Amazon
by Zacks Equity Research
CVS Health, Herbalife, Rite Aid and Amazon are part of the Zacks Industry Outlook article.
Top Analyst Reports for Merck, Salesforce & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).